Evaluation of the Direct Agglutination Test and the rK39 Dipstick Test for the Sero-diagnosis of Visceral Leishmaniasis

Henk DFH Schallig†, Marilene Canto-Cavalheiro*, Eduardo S da Silva**

KIT (Koninklijk Instituut voor de Tropen/Royal tropical Institute), Biomedical Research, Meibergdreef 39, 1105 AZ Amsterdam, The Netherlands †Laboratório de Bioquímica de Tripanosomatídeos, Departamento de Imunologia, Instituto Oswaldo Cruz-Fiocruz, Rio de Janeiro, RJ, Brasil **Laboratório de Leishmanioses, Centro de Pesquisas René Rachou-Fiocruz, Belo Horizonte, MG, Brasil and Centro de Pós-graduação e Pesquisas/Fundação Educacional de Divinópolis, Universidade do Estado de Minas Gerais, Divinópolis, MG, Brasil

The direct agglutination test (DAT) based on a freeze-dried antigen and the rK39 dipstick test were evaluated for the sero-diagnosis of visceral leishmaniasis (VL). The sensitivity and specificity of both tests were determined using sera from confirmed VL patients (n = 21), healthy controls (n = 19) and from patients with other confirmed infectious diseases (n = 42). The DAT had a sensitivity and a specificity of 100%. The rK39 had a sensitivity of 85.7% and a specificity of 82%. Both tests were also used to screen blood samples of confirmed VL patients (n = 15) and serum samples of VL suspects (n = 61). The DAT found all blood samples of confirmed VL patients positive and tested 98.4% of the serum samples of the VL suspects positive. In contrast, rK39 detected in 9/15 blood samples (60%) antibodies against Leishmania chagasi and found 85.3% of the serum samples of the suspected patients positive. Although the rK39 dipstick is more rapid and user friendlier than the DAT, the latter has a superior sensitivity and specificity. Furthermore, the reagents used for DAT do not require cold storage, whereas the buffer of the rK39 must be stored at 4°C. Therefore, the DAT is the most suitable test for the sero-diagnosis of VL under field conditions.

Key words: visceral leishmaniasis - direct agglutination test - rK39 dipstick test - Leishmania chagasi - diagnosis - human - Brazil
sera from Ethiopian patients (n = 10; a gift from Institute of Pathobiology, University of Addis Ababa, Ethiopia) and Brazilian (n = 11; a gift from the Leishmaniasis Laboratory of the Centro de Pesquisas Rene Rachou-Fiocruz, Belo Horizonte, Minas Gerais, Brazil) with active microscopically proven VL (n = 21; positive control sera); (2) healthy blood donors from Manaus (Amazonas, Brazil) who had no history of VL and no clinical symptoms of leishmaniasis (n = 19; negative control sera); (3) sera from patients with other confirmed diseases: cutaneous leishmaniasis (n = 5 from Belo Horizonte, Minas Gerais); Chagas disease (n = 12 from Recife, Pernambuco, Brazil); African trypanosomiasis (n = 5 from Uganda); leprosy (n = 5 from Indonesia); malaria (n = 5 from Kenya); tuberculosis (n = 5 from Kenya); toxoplasmosis (n = 5 from the Netherlands).

Furthermore, the study used clinical samples (serum and blood) of Brazilian individuals. The samples examined are part of the collection at the Leishmaniasis Laboratory of the Centro de Pesquisas Rene Rachou-Fiocruz. All samples were sent to the laboratory under the existing health care system of Metropolitan Region of Belo Horizonte, Minas Gerais, Brazil and stored at -20°C. The following two groups of samples were included in the present study: (1) whole blood samples of patients with active VL, microscopically proved (n = 15); (2) serum samples of patients clinically suspected of VL, all patients had an enlarged spleen, a prolonged irregular fever and anemia and were living in endemic area (n = 61).

**DAT** - The DAT was performed essentially as described previously (Meredith et al. 1995, Oskam et al. 1999). In brief, the serum or blood samples were diluted in physiological saline (0.9% NaCl) containing 0.8% β-mercaptoethanol. Two-fold dilution series of the sera were made, starting at a dilution of 1:100 and going up to a maximum serum dilution of 1:102.400. Freeze-dried DAT antigen (*L. donovani* promastigotes) produced by KIT Biomedical Research was reconstituted with physiological saline according to the manufacturer’s instructions. Fifty µl DAT antigen solution (concentration of 5 x 10^7 parasites per ml) was added to each well containing 50 µl diluted serum and the results were read after 18 h of incubation at room temperature. Appropriate control samples with known DAT titres were included as controls. A sample is considered positive if it has a titre ≥ 1:1600, the cut-off value of the DAT (ES da Silva, unpublished results).

**RK39 dipstick test** - Dipsticks were purchased from InBios International (Seattle, USA) and the test was performed according to the manufacturer’s instruction. The reading of the test was done after exactly 10 min. A dipstick was considered positive as both the internal control and the test band were stained (irrespective of the intensity of the staining). A dipstick was considered negative as only the internal control was visible. The result of a dipstick was considered not valid if the internal control was not stained.

**Reproducibility** - Two observers independently read the results of DAT and dipstick assays and their results were compared afterwards. In the case that the interpretation of the dipstick results was different between the two observers or that the reading of the DAT differed more than one serum dilution step the sample was re-tested in the appropriate test. In the case that the result of the dipstick and the DAT differed from each other, the sample was re-analysed in both tests to confirm the test results.

**Determining sensitivity and specificity of the tests** - The sensitivity (i.e. the probability that the assay will be positive when the infection is present) and the specificity (i.e. the probability that the assay will be negative when the infection is absent) were calculated using the formulas: Sensitivity = TP/(TP+FN) x 100% and Specificity = TN/(TN+FP) x 100%. Where TN represents true negative, TP true positive, FN false negative and FP false positive. The sensitivity of the two tests was assessed with sera from confirmed VL patients (n = 21). Sera of healthy controls (n = 19) and sera of patients with confirmed other diseases (n = 42) were used to determine the specificity of DAT and rK39 dipstick.

**RESULTS**

**Reproducibility** - Neither the DAT nor rK39 dipstick test had to be repeated due to inconsistencies between the readings of the observers. A 100% agreement in the reading of the dipstick test and the DAT (one step difference in titre was allowed) was found between the two observers. The analysis performed with rK39 dipstick test and DAT were all valid as the internal control of the dipstick was always positive and the titres of appropriate control samples determined with DAT correspond to the pre-determined titre of the control (one step difference in DAT titre was allowed).

Fourteen samples of which a different result was obtained with DAT and rK39 dipstick were re-tested with both tests and in all cases re-testing resulted in the same test result as initially obtained.

**Sensitivity and specificity of DAT and rK39 dipstick test** - The results of DAT and rK39 testing of positive and negative controls and of the serum samples of patients with other confirmed infectious diseases are summarised in Table I. Calculation of the sensitivity of the assays revealed that the DAT had a sensitivity of 100% (no false negative results) and the rK39 had a sensitivity of 85.7% (three false negative results). None of the negative control samples and samples from patients with other confirmed infectious diseases tested positive with DAT (all titres < 1:1600; 100% specificity). In contrast, a positive (albeit sometimes faint) reaction was observed with the rK39 dipstick with some of the serum samples of patients with other confirmed infectious diseases (8/42) or healthy endemic controls (3/19). The calculated specificity of the rK39 dipstick on the basis of the results obtained in the present study is 82%.

The DAT found 14/15 blood samples of confirmed VL patients positive (93.3%). In contrast, rK39 detected in only 9/15 blood samples (60%) antibodies against *L. chagasi*.

**Evaluation of serum samples of Brazilian VL suspects** - The results of DAT and rK39 testing of serum samples of clinical suspects (n = 61) are summarised in Table II. The DAT tested 98.4% of the serum samples of the VL suspects positive, whereas rK39 found 85.3% of
the serum samples of the suspected patients positive. Fifty-two samples were positive for both DAT and rK39. Furthermore, DAT was positive for another eight suspects, but these were negative with rK39. Only one sample tested negative with both tests.

### TABLE I

Comparison between direct agglutination test (DAT) and rK39 dipstick using serum samples of confirmed visceral leishmaniasis (VL) patients, blood samples of confirmed VL patients, healthy endemic controls and samples from patients with other confirmed infectious diseases

<table>
<thead>
<tr>
<th>Patient category</th>
<th>Result with DAT</th>
<th>Result with rK39</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum samples VL patients</td>
<td>21/21</td>
<td>18/21</td>
</tr>
<tr>
<td>Blood samples VL patients</td>
<td>14/15</td>
<td>9/15</td>
</tr>
<tr>
<td>Healthy controls</td>
<td>0/19</td>
<td>3/19</td>
</tr>
<tr>
<td>Cutaneous leishmaniasis</td>
<td>0/5</td>
<td>1/5</td>
</tr>
<tr>
<td>Chagas disease</td>
<td>0/12</td>
<td>4/12</td>
</tr>
<tr>
<td>African trypanosomiasis</td>
<td>0/5</td>
<td>1/5</td>
</tr>
<tr>
<td>Leprosy</td>
<td>0/5</td>
<td>1/5</td>
</tr>
<tr>
<td>Malaria</td>
<td>0/5</td>
<td>0/5</td>
</tr>
<tr>
<td>Toxoplasmosis</td>
<td>0/5</td>
<td>0/5</td>
</tr>
<tr>
<td>Tuberculosis</td>
<td>0/5</td>
<td>1/5</td>
</tr>
</tbody>
</table>

The number represents the number of samples found positive by the test/total number of samples tested.

### TABLE II

Comparison between direct agglutination test (DAT) and rK39 dipstick using serum samples from suspect visceral leishmaniasis patients

<table>
<thead>
<tr>
<th>DAT</th>
<th>rK39+</th>
<th>rK39 -</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>+</td>
<td>52</td>
<td>8</td>
<td>60</td>
</tr>
<tr>
<td>-</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Total</td>
<td>52</td>
<td>9</td>
<td>61</td>
</tr>
</tbody>
</table>

### DISCUSSION

In the present study, the rK39 test had a lower sensitivity than the DAT based on the freeze-dried antigen. It failed to detect antibodies in three serum samples (one from Ethiopian origin and two from Brazilian origin) of parasitologically confirmed VL patients. This is in line with observations of Zijlstra et al. (2001) who also found a lower sensitivity (67%) of the rK39 compared to DAT when testing serum samples from African VL patients in Sudan. In addition, Veeken (2001) has observed a low specificity (59-70%) of the rK39 test. In contrast, Sundar et al. (1998) reported a 100% sensitivity for the test using peripheral blood samples from Indian patients. This observation was confirmed by Bern et al. (2000) in a study in Nepal. These observation suggest a regional limitation of the use of the rK39 test.

Although not the intended use of the test, according to the manufacturer’s instructions, the sensitivity of the rK39 test was also evaluated in the present study with blood samples of confirmed VL patients from the collection at the Leishmaniasis Laboratory of the Centro de Pesquisas Rene Rachou-Fiocruz (n = 15). The sensitivity of rK39 was in this case low, 60%, whereas DAT found 14 out of the 15 tested samples positive (93.3% positive).

The specificity of both tests was assessed by using sera from healthy controls and from patients with other confirmed infectious diseases. Several samples of healthy endemic controls tested positive with the dipstick, but not with DAT. This is in line with observations of Zijlstra et al. (2001) who also found healthy Sudanese controls without any history of VL positive with the rK39 dipstick (sensitivity of 96.8%). More importantly, the rK39 dipstick showed in several cases cross reactions with serum samples of patients with other infectious diseases, among which is Chagas disease (33% false positives) an infection in which the acute phase should always be included in the differential diagnosis of any unknown fever in the Brazilian situation.

The sensitivity and specificity of the DAT in the present study were determined on a limited number of healthy subjects, patients with visceral leishmaniasis and patients with various other diseases. Therefore 100% sensitivity and specificity are not claimed and cross-reactions can not be fully excluded. It is important to determine the cut-off value of the test using a large as possible number of appropriate local endemic controls (Oskam et al. 1999). Because of the promising results obtained in the present study a large field evaluation of the DAT in different regions of Brazil will be undertaken.

Although the rK39 dipstick has an ideal format for use in the field, as it is a rapid and simple test not requiring extensive training of the operator, its lower sensitivity and specificity limits its use for the sero-diagnosis of VL in Brazil. Furthermore, the test requires cold storage of the running buffer, the test strips can not be stored at high ambient temperatures and the test can not be performed with blood samples. In contrast, the DAT based on freeze-dried antigen does not require cold storage of reagents and can be performed with blood samples. A limitation of the DAT is the relatively long incubation time (18 h) and the fact that serial dilutions of blood or serum must be made.

Finally, we would like to emphasise that serological tools are an aid in the diagnosis of VL. The outcome of either rK39 dipstick test or DAT should always be judged judiciously in connection with clinical, epidemiological and other diagnostic data.

### ACKNOWLEDGEMENTS

To Professor Asrat Hailu (Institute of Pathobiology, University of Addis Ababa, Ethiopia) for providing us with positive control samples, Dr Birgit van Benthem (KIT Biomedical Research) for critical reading of the manuscript and Nel Kroon (KIT Biomedical Research) and Gerard Schoone (KIT Biomedical Research) for expert technical assistance.

### REFERENCES


